PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 145 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.11 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $430,541 | -96.0% | 15,588 | -96.7% | 0.00% | -96.2% |
| Q1 2023 | $10,702,429 | +486.1% | 465,323 | +178.0% | 0.05% | +430.0% |
| Q4 2022 | $1,825,996 | -49.2% | 167,369 | -60.7% | 0.01% | -47.4% |
| Q3 2022 | $3,594,000 | -23.8% | 426,393 | -28.5% | 0.02% | -20.8% |
| Q2 2022 | $4,718,000 | +160.1% | 596,487 | +678.7% | 0.02% | +140.0% |
| Q1 2022 | $1,814,000 | -71.1% | 76,601 | -58.3% | 0.01% | -70.6% |
| Q4 2021 | $6,281,000 | -35.6% | 183,648 | -66.6% | 0.03% | -46.0% |
| Q3 2021 | $9,747,000 | +3238.0% | 550,083 | +8357.6% | 0.06% | +3050.0% |
| Q2 2021 | $292,000 | – | 6,504 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |